Gracell Biotechnologies (GRCL) Short Interest Ratio & Short Volume

Short interest is the volume of Gracell Biotechnologies shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 1,190,000 shares of GRCL short. 1.64% of Gracell Biotechnologies' shares are currently sold short. Learn More on Gracell Biotechnologies' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GRCL shares currently have a short interest ratio of 1.0. Learn More on Gracell Biotechnologies's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.64% of Gracell Biotechnologies' floating shares are currently sold short.

Gracell Biotechnologies saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 1,190,000 shares, an increase of 171.6% from the previous total of 438,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Gracell Biotechnologies currently has issued a total of 72,678,000 shares. Some of Gracell Biotechnologies' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Gracell Biotechnologies currently has a public float of 72,660,000 shares.

1.64% of Gracell Biotechnologies' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Gracell Biotechnologies: Allogene Therapeutics, Inc. (28.20%), Poseida Therapeutics, Inc. (4.68%), Kura Oncology, Inc. (15.69%), CureVac (5.12%), Mind Medicine (MindMed) Inc. (37.98%), PepGen Inc. (3.75%), Orchestra BioMed Holdings, Inc. (3.51%), Renovaro Inc. (4.29%), bluebird bio, Inc. (44.81%), BriaCell Therapeutics Corp. (1.57%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Co. ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks.

Short selling GRCL is an investing strategy that aims to generate trading profit from Gracell Biotechnologies as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Gracell Biotechnologies occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GRCL, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GRCL, twice per month. The most recent reporting period available is January, 31 2024.